Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:18 AM
Ignite Modification Date:
2025-12-25 @ 4:18 AM
NCT ID:
NCT04694820
Eligibility Criteria:
Inclusion Criteria:
* PHASE 1: Patients diagnosed with chronic myeloid leukemia
* PHASE 1: Initiated tyrosine kinase inhibitors therapy for a year
* PHASE 1: Able to read and understand English
* PHASE 1: Able to provide informed consent
* PHASE 1: Have a mobile phone with TXT capability
* PHASE 1: Know how to use TXT
* PHASE 2: Patients diagnosed with chronic myeloid leukemia in the chronic phase
* PHASE 2: Starting tyrosine kinase inhibitors therapy or has been on tyrosine kinase inhibitors with anticipation of at least 6 month duration of use
* PHASE 2: Able to read and understand English
* PHASE 2: Able to provide informed consent
* PHASE 2: Have a mobile device with TXT capability
* PHASE 2: Willing to use a wireless pill bottle during study for 6 months
* PHASE 2: Know or willing to learn how to use TXT
Exclusion Criteria:
• Cognitive impaired document in the electronic medical record (EMR)
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT04694820
Study Brief:
Protocol Section:
NCT04694820